Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
37.84
+1.63 (4.50%)
At close: Aug 6, 2025, 4:00 PM
37.72
-0.12 (-0.32%)
After-hours: Aug 6, 2025, 4:29 PM EDT

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.

In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.

Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals logo
CountryUnited States
Founded2007
IPO DateJul 24, 2013
IndustryBiotechnology
SectorHealthcare
Employees488
CEOBrian Goff

Contact Details

Address:
88 Sidney Street
Cambridge, Massachusetts 02139
United States
Phone617 649 8600
Websiteagios.com

Stock Details

Ticker SymbolAGIO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001439222
CUSIP Number00847X104
ISIN NumberUS00847X1046
SIC Code2834

Key Executives

NamePosition
Brian M. Goff M.B.A.Chief Executive Officer and Director
Cecilia JonesChief Financial Officer
James William BurnsCorporate Secretary and Chief Legal Officer
Dr. Sarah Gheuens M.D., Ph.D.Chief Medical Officer and Head of Research and Development
Tsveta MilanovaChief Commercial Officer
Dr. Lewis clayton Cantley Ph.D.Co-Founder
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.Co-Founder
Dr. Craig B. Thompson M.D.Co-Founder
Dr. Shin-San Su Ph.D.Co-Founder
T. J. WashburnVice President, Controller and Principal Accounting Officer

Latest SEC Filings

DateTypeTitle
Aug 4, 20258-KCurrent Report
Jul 31, 202510-QQuarterly Report
Jul 31, 20258-KCurrent Report
Jul 17, 2025SCHEDULE 13G/AFiling
Jul 10, 2025144Filing
Jul 9, 2025144Filing
Jul 8, 20258-KCurrent Report
Jul 7, 2025SCHEDULE 13GFiling
Jul 1, 2025144Filing
Jun 24, 2025144Filing